Daniel K. Turner III

Daniel K. Turner III has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Orexigen Therapeutics, Inc., Paratek Pharmaceuticals, Inc. and NeurogesX Inc. We count 33 filings; the first trade dates from 1 May 2007 and the latest from 22 December 2011.

On the open market, the record shows 3 purchases worth €880k and 21 sales worth €4.8M. The totals do not cover 3 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 3 share grants. 2012 to date brings 2 purchases and no sales.

A typical purchase (the median) is worth €32k.

The latest filing, published on 6 February 2012, reports an open-market purchase of €32k in Orexigen Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.